**Olink Bioscience introduces a new 92-protein biomarker panel for oncology research**

**Uppsala, Sweden, December 2, 2015 -** Olink Bioscience today launched [**Proseek® Multiplex Oncology II96x96**](http://www.olink.com/onc2) a new human protein biomarker panel that targets the cancer research area. This is part of the on-going development of the Proseek platform, expanding the library of unique biomarkers available and complementing the existing panels directed against cardiovascular and inflammatory diseases. With the launch of this new panel, Olink can now provide more than 350 unique protein biomarker assays, and this offering will be significantly expanded in early 2016 with a panel focused on the clinically important field of neurology.

Proseek Multiplex Oncology II96x96 will be an important tool in the search for new protein signatures (expression patterns based on the measurement of multiple proteins) that could be used to improve the understanding, prediction and prognosis of cancer, the discovery of new drug targets, and in the development of more effective and personalized therapy for future patients. Cancer is still one of the major causes of death and continues to require massive global research efforts. Complementing and enhancing the valuable contributions made by extensive genome-based studies in the cancer field, the ability to discover and validate more protein biomarkers is likely to be increasingly important in addressing this huge healthcare challenge.

“Global healthcare has to move towards more effective strategies where the appropriate treatments are selected for the individuals who will respond best to a specific therapeutic option (often called personalized or precision medicine). This is clearly the future of medicine, but achieving it requires effective ways to identify and stratify the patients so that clinicians understand how they will respond to any given treatment. By rapidly and accurately measuring many protein biomarkers simultaneously from small volumes of patient samples, Proseek Multiplex has enormous potential to become a valuable tool in these exciting developments for future healthcare improvements. The real journey towards precision medicine is just beginning, and Olink plans to be the partner of choice for those driving this revolution, every step of the way” says Andrea Ballagi, VP Sales & Marketing at Olink Bioscience.

**Product and technology information**
Proseek Multiplex Oncology II96x96 offers high-throughput multiplex immunoassays that measure 92 cancer-related proteins across 96 samples simultaneously using only one microliter of serum, plasma, or almost any other type of biological sample. This panel replaces and improves on our successful Proseek Multiplex Oncology I v296x96 panel, offering 60 completely new oncology-focused biomarker assays. The composition of the panel was designed to maximize the number of useful oncology markers, as well as the overall performance of the assays. Using Proseek Multiplex, researchers can analyze thousands of samples per week, which greatly accelerates the speed of protein biomarker research.

Proseek Multiplex is based on the proprietary **[Proximity Extension Assay (PEA) technology](http://www.olink.com/technology/pea-technology)** developed by Olink Bioscience. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity and enables Proseek Multiplex to achieve a combination of high multiplexing level and data quality that cannot be matched using standard immunoassay techniques. An animation overviewing how the technology works and what it is used for can be viewed on Olink’s [YouTube channel](https://www.youtube.com/watch?v=aHqZzHMPXqg).

For research use only. Not for use in diagnostic procedures.

**About Olink Bioscience**
Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Bioscience aims to provide outstanding products and services for human protein biomarker research and development. Our groundbreaking solutions help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Our Proseek® Multiplex immunoassay panels enable rapid, high-throughput analysis with exceptional data quality and minimal consumption of precious biological samples. Only 1 µL of sample is needed to address 92 biomarkers simultaneously and each panel is sufficient for 96 samples, generating more than 9 000 data points from each run. Each Proseek Multiplex panel is focused on a specific area of disease or biology, targeting 92 validated and exploratory biomarkers that have been carefully selected in collaboration with leading experts in the field. All assays are rigorously quality controlled and our validation data is made freely available. Customers can obtain Proseek Multiplex as ready-to-use kits to run the assays themselves, or can choose to let our in-house experts run their samples for them, using our Proseek Multiplex Analysis Service.

Olink Bioscience is headquartered in Uppsala, Sweden.

For more information, please visit [www.olink.com.](file:///C%3A%5CUsers%5CEmmaRennel%5CAppData%5CLocal%5CMicrosoft%5CWindows%5CTemporary%20Internet%20Files%5CContent.Outlook%5C5NUQDDMM%5Cwww.olink.com)

Olink and Proseek are trademarks or registered trademarks of Olink AB.

**Contact information**
Andrea Ballagi, MD, PhD, MBA
VP Sales & Marketing
Phone: +46-18-444 3970
E-mail: info@olink.com